Precision BioSciences, Inc.

NasdaqCM:DTIL Stok Raporu

Piyasa değeri: US$185.3m

Precision BioSciences Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Precision BioSciences yıllık ortalama 12% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 33.8% annual. Gelirler azalıyor .

Anahtar bilgiler

12.03%

Kazanç büyüme oranı

48.23%

EPS büyüme oranı

Biotechs Sektör Büyümesi17.04%
Gelir büyüme oranı-18.13%
Özkaynak getirisi-58.46%
Net Marj-98.70%
Son Kazanç Güncellemesi31 Mar 2026

Yakın geçmiş performans güncellemeleri

Recent updates

Analiz Makalesi • May 13

Analyst Forecasts For Precision BioSciences, Inc. (NASDAQ:DTIL) Are Surging Higher

Precision BioSciences, Inc. ( NASDAQ:DTIL ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Dec 29

Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026

Summary Precision BioSciences offers high-risk, high-reward potential, trading below cash with key HBV and DMD data catalysts expected in 2026. PBGENE-HBV targets both cccDNA and integrated HBV DNA, aiming for a functional HBV cure superior to downstream competitors. Recent $75M capital raise extends DTIL's cash runway through major readouts, supporting continued clinical development and operational flexibility. Risks include potential safety events, competitive efficacy, and uncertain milestone/royalty revenue from partnered programs. Read the full article on Seeking Alpha
Analiz Makalesi • Aug 06

Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts

Celebrations may be in order for Precision BioSciences, Inc. ( NASDAQ:DTIL ) shareholders, with the analysts delivering...
Analiz Makalesi • Jun 23

It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks

Precision BioSciences, Inc. ( NASDAQ:DTIL ) shares have had a horrible month, losing 29% after a relatively good period...
Analiz Makalesi • Mar 14

Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analiz Makalesi • Dec 08

Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Sep 02

Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles

Precision BioSciences promoted Cindy Atwell to chief business officer and carried out other leadership changes. Atwell, who was serving as senior vice president of Business Development and Alliance Management, will continue to oversee the Business Development and Alliance functions with added responsibility for Project and Portfolio Management, the company said in a Sept. 2 press release. Jeff Smith, co-founder and formerly chief technology officer, was promoted to chief research officer and will assume responsibility for the management and direction of the company’s research programs and report directly to the CEO Michael Amoroso. Precision added that Derek Jantz, co-founder and chief scientific officer, will step down from the board to focus his time partnering with Amoroso in making company strategy and managing relationships with external stakeholders. Jantz departure would reduces the number of management members serving on the board, the company added. DTIL +1.27% to $1.60 premarket Sept. 1
Seeking Alpha • Aug 16

Precision BioSciences: CAR T Data Updates End Of 2022 And Plenty Of Cash

PBCAR0191 is being explored in a phase 1/2 study in patients with relapsed/refractory Non-Hodgkin Lymphoma and r/r B-cell Acute Lymphoblastic Leukemia. Data updates from PBCAR0191, PBCAR19B for non-Hodgkin's Lymphoma and PBCAR269A for multiple myeloma are expected before end of 2022. Precision has established several partners for use of its ARCUS in vivo gene editing platform; these partners are Eli Lilly, Novartis and iEcure. Company has enough cash to fund its operations until the end of 2024, giving plenty of cash runway for the foreseeable future. Precision BioSciences, Inc. (DTIL) is a great speculative biotech play to look into. That's because it is advancing an allogeneic CAR-T pipeline, along with an in vivo gene editing pipeline. Speaking of its CAR-T treatments, the main one in the pipeline would be PBCAR0191, which is being explored in a phase 1/2 study in patients with relapsed/refractory (r/r) Non-Hodgkin Lymphoma ((NHL)) and r/r B-cell Acute Lymphoblastic Leukemia. In the most recent interim update, it noted that relapsed patients given this CAR T were able to achieve a 100% response rate. Why I believe it may have some potential upside is because Precision expects to release updated results from this very same study before the end of 2022. In addition, it has a pretty solid pipeline when it comes to in vivo gene editing as well. It has several wholly owned treatments and then it has many others which have already been partnered with a few pharmaceutical companies. With proof of concept established using PBCAR0191 for the treatment of patients with relapsed/refractory NHL B-cell ALL, plus an update on data from the phase 1/2 study expected before the end of 2022, these are the reasons why I believe that Precision Biosciences is a great speculative biotech play to look into. PBCAR0191 For Treatment Of Patients With Non-Hodgkin's Lymphoma And B-Cell Acute Lymphoblastic Leukemia The main program to go over involves the use of PBCAR0191, which is being developed for the treatment of patients with non-Hodgkin's lymphoma ((NHL)) and B-Cell Acute Lymphoblastic Leukemia (B-ALL). Lymphoma is cancer that develops in the lymphatic system, which is the body's fighting immune system network. The lymphatic system is composed of: Lymph Nodes, spleen, thymus gland and bone marrow area. This type of cancer affects these organs and several others. There are two main types of lymphomas that you are likely aware of, which are: Hodgkin's Lymphoma Non-Hodgkin's Lymphoma These are the two main ones, although there are some other types. Both of these types are lymphomas that have problems with the B-cells in the body, which are responsible for fighting off infections in a person's body. The main difference is found under a microscope where each of the cells are shown to be different. This is not the only difference between Hodgkin's and Non-Hodgkin's lymphoma. Hodgkin's Lymphoma is a rare type of lymphoma and only about 8,500 cases diagnosed in 2016. This compares to Non-Hodgkin's Lymphoma which had 72,500 cases were diagnosed in 2016 and is the seventh most diagnosed type of cancer. In addition, there is a difference in 5-year survival rates, which are shown directly below: Hodgkin's Lymphoma - More than 86% of patients diagnosed with this type of cancer survive 5 years or more Non-Hodgkin's Lymphoma - More than 70% of patients diagnosed with this type of cancer survive 5 years or more The main thing is that a majority of biotechs targeting the large non-Hodgkin's lymphoma market. That's because the global Non-Hodgkin's Lymphoma market is expected to reach $12.5 billion by 2027. This is a very large market opportunity for Precision Biosciences. The use of PBCAR0191 is being explored in an ongoing phase 1/2a study, which demonstrated that it could achieve high response rates in patients who relapsed after CAR T. This trial is an open-label, dose-escalation and dose expansion study to evaluate safety and efficacy of PBCAR0191 in patients with relapsed/refractory (r/r) Non-Hodgkin Lymphoma ((NHL)) and r/r B-cell Acute Lymphoblastic Leukemia. Speaking of dose level and dose expansions, it is expected that Precision Biosciences could reach up to 6 dose levels total. What I will show below is that the biotech was able to achieve high response rates in a very sick patient population. How sick? Well consider that these are CAR T relapsed patients who received on average 5 prior lines of treatments. That means they gone through and failed multiple types of treatments, along with other CAR T, before entering this particular study. The positive results released as an update in June of 2022 layout the most recent dose levels which were used for this study. These dose levels used for PBCAR0191 were dose level 3 (DL3) with enhanced lymphodepletion (treatment to kill existing T-cells to make room for new ones) in 6 patients and then dose level 4 (DL4b) with reduced/decreasing lymphodepletion in another 6 patients (This dose level is referred to as the "New Cohort" or latest cohort as of January 2022). As of the May 31, 2022 cutoff date, the breakdown for each dose level cohort noted directly above is as follows: It noted that 11 out of 11 (100%) of patients achieved an objective response rate (ORR) It was said that 8 out of 11 patients achieved a complete response rate 6 patients from the pool of 11 patients remain with an ongoing response for 18 months + The data for which I highlighted above deals with both dose level cohorts (DL3 and DL4b). However, what I find intriguing is that the dose level 4b cohort (new cohort), had shown to be superior over dose level 3. This was even achieved with a reduction of lymphodepletion as well, which is always good for safety in the end. This is good news for Precision Biosciences, because it is targeting a huge unmet need. These are patients with aggressive lymphomas who fail on autologous CAR Ts and other therapies. There is no approved standard of care ((SOC)) for these patients and their progression-free survival for the time being is a mere 2 months. As far as a catalyst goes, there will be an update on the use of PBCAR0191 for the treatment of patients with relapsed/refractory NHL towards the end of 2022. In addition, to updates on the other CAR Ts in the pipeline which are PBCAR19B and PBCAR269A, which are being developed for the treatment of patients with NHL and Multiple Myeloma ((MM)) respectively. It will likely be an update on data and maybe even plans for the next study. The biotech intends to meet with the FDA to discuss the data observed and then see what it needs to do next to advance it. The hope is that it can continue to reduce the amount of lymphodepletion patients need with treating their aggressive lymphomas. This could both improve safety and efficacy of PBCAR0191. Two Massive Partnerships Worth Billions Of Dollars In Potential Milestone Payments The thing is that Precision Biosciences uses its ARCUS gene editing technology for its pipeline. It remains to be seen how well it does when it is actually utilized in humans, however, it has already attracted the attention of several pharmaceutical companies. One of the most recent partnerships for licensing the ARCUS in vivo gene editing technology involves Novartis (NVS). Novartis wanted to enter this deal to get its hands on the ARCUS gene editing technology. Precision Biosciences received an upfront payment of $75 million. That's a good start to help fund its operations, but the real deal happens if it can meet all of its milestones and earn up to $1.4 billion in cash. Of course, should any product reach the market it will obtain the usual tiered royalties on sales. Its main job will be to develop a single ARCUS nuclease that is safe and efficient for In Vivo gene insertion. The goal is to attempt to develop cures for large markets like sickle cell disease and beta thalassemia. The thalassemia market is expected to reach $3.53 billion in 2022. On the other hand, the other market opportunity is much larger. It is expected that the sickle-cell disease market will reach $5.5 billion in 2023. These are the initial indications for which Novartis wants to happen. I believe that an in vivo ARCUS nuclease will be developed. The test is whether or not such a product is efficient when it delivered to humans in a phase 1 study. These indications are just the start of what is possible. That's because the partnership could eventually expand to other hemoglobinopathies that exist out there.

Gelir ve Gider Dağılımı

Precision BioSciences nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqCM:DTIL Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
31 Mar 2645-443054
31 Dec 2534-473254
30 Sep 251-843456
30 Jun 251-783655
31 Mar 2551-223560
31 Dec 246973560
30 Sep 2475113556
30 Jun 2488163659
31 Mar 2458-203656
31 Dec 2349-433953
30 Sep 2352-494350
30 Jun 2347-314326
31 Mar 2331-594435
31 Dec 2225-734344
30 Sep 2221-764755
30 Jun 2238-934492
31 Mar 22102-4044106
31 Dec 21116-3143112
30 Sep 21118-3242109
30 Jun 21101-4742106
31 Mar 2134-1014095
31 Dec 2024-1093995
30 Sep 2022-1063892
30 Jun 2019-1013787
31 Mar 2024-883584
31 Dec 1922-933079
30 Sep 1921-872577
30 Jun 1918-762167
31 Mar 1915-691756
31 Dec 1811-461544
30 Sep 187-381235
31 Dec 176-21919
31 Dec 167-879

Kaliteli Kazançlar: DTIL şu anda kârlı değil.

Büyüyen Kar Marjı: DTIL şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: DTIL kârlı değildir, ancak son 5 yılda zararlarını yılda 12% oranında azaltmıştır.

Büyüme Hızlandırma: DTIL 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: DTIL kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 43% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: DTIL hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -58.46% ) sahiptir.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/21 19:11
Gün Sonu Hisse Fiyatı2026/05/21 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Precision BioSciences, Inc. 9 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Debjit ChattopadhyayGuggenheim Securities, LLC
Debjit ChattopadhyayH.C. Wainwright & Co.
Patrick TrucchioH.C. Wainwright & Co.